Lercanidipine hydrochloride

Cardiovasc®, Corifeo®, Carmen®, Lerzam®, Lercanidipine HCl, Rec-15/2375, Lercadip®, Lercapin®
A Potent and Selective Blocker of L-type CaV Channels
Cat #: L-115
Alternative Name Cardiovasc®, Corifeo®, Carmen®, Lerzam®, Lercanidipine HCl, Rec-15/2375, Lercadip®, Lercapin®
  • Lyophilized Powder
  • Bioassay Tested
  • Source Synthetic
    MW: 648.2
    Purity: >98%
    Effective concentration 1-100 µM.
    Chemical name 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester hydrochloride.
    Molecular formula C36H42ClN3O6.
    CAS No.: 132866-11-6.
    Activity 10 µM were effective in abolishing Ang II mediated smooth muscle contraction1.
      • Arun, K.H. et al. (2005) Cardiovasc. Res. 65, 374.

    Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
    Solubility DMSO. Centrifuge all product preparations before use (10000 x g 5 min).
    Storage of solutions Up to four weeks at 4°C or three months at -20°C.
      • Alomone Labs Lercanidipine hydrochloride inhibits L-type voltage-gated Ca2+ currents expressed in  Xenopus oocytes.
        A. Time course of CaV1.2/α2-δ1/β2a current inhibition by 10 and 30 µM Lercanidipine hydrochloride (#L-115). Currents were elicited by application of voltage steps from a holding potential of -80 mV to 0 mV (100 msec). B. Superimposed example traces of current responses before and during perfusion of 10 and 30 µM Lercanidipine hydrochloride (as indicated).
      • Bers, D.M. et al. (1999) Cardiovasc. Res. 42, 339.
      • Hockerman, G.H. et al. (2000) Annu. Rev. Pharmacol. Toxicol. 37, 361.
      • Hair, P.I. et al. (2007) Drugs 67, 95.
      • Rimoldi, E. et al. (1994) Acta. Therap. 20, 23.
      • Agrawal, R. et al. (2006) J. Hypertens. 24,185.
      • Ca2+ influx via voltage-dependent L-type Ca2+ channels (CaV1.2) found in cardiac and vascular smooth muscle initiates contraction and contributes to timing of the cardiac action potential1. CaV1.2 is sensitive to block by three distinct classes of small-molecule drugs: dihydropyridines (DHPs), phenylalkylamines (PAAs), and benzothiazepines (BZPs)2.

        Lercanidipine hydrochloride is antihypertensive drug structurally related to dihydropyridine (DHP) calcium channel blockers3. It is similar to other pheripheral vasodialators. It inhibits the influx of extracellular Ca2+ across the mycocardial and vascular smooth muscle cell membranes4. The effect of lercanidipine hydrochloride has also successfully evaluated in severe or resistant hypertension, elderly subjects, and diabetics5.

    Target L-type Ca2+ channels
    Last update: 01/01/2019

    Lercanidipine hydrochloride (#L-115) is a highly pure, synthetic, and biologically active compound.

    For research purposes only, not for human use